Lili Gao, Teruo Utsumi, Keitaro Tashiro, Bo Liu, Dahai Zhang, E. Scott Swenson, Yasuko Iwakiri – 8 January 2013 – Nogo‐B, also known as reticulon 4B, promotes liver fibrosis and cirrhosis by facilitating the transforming growth factor β (TGF‐β) signaling pathway in activated hepatic stellate cells. The aim of this study was to determine the role of Nogo‐B in hepatocyte proliferation and liver regeneration. Partial hepatectomy (PHx, 70% resection) was performed in male wild‐type (WT) and Nogo‐A/B knockout mice (referred to as Nogo‐B KO mice).

Elena Bellafante, Stefania Murzilli, Lorena Salvatore, Dominga Latorre, Gaetano Villani, Antonio Moschetta – 8 January 2013 – Development of hepatic steatosis and its progression to steatohepatitis may be the consequence of dysfunction of several metabolic pathways, such as triglyceride synthesis, very low‐density lipoprotein (VLDL) secretion, and fatty acid β‐oxidation. Peroxisome proliferator‐activated receptor γ coactivator‐1β (PGC‐1β) is a master regulator of mitochondrial biogenesis and oxidative metabolism, lipogenesis, and triglyceride (TG) secretion.

Calogero Cammà, Giuseppe Cabibbo, Salvatore Petta, Marco Enea, Massimo Iavarone, Antonio Grieco, Antonio Gasbarrini, Erica Villa, Claudio Zavaglia, Raffaele Bruno, Massimo Colombo, Antonio Craxì, on behalf of the WEF and the SOFIA study groups – 8 January 2013 – The purpose was to assess the cost‐effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study.

Yingjian Liang, Tongsen Zheng, Ruipeng Song, Jiabei Wang, Dalong Yin, Luoluo Wang, Haitao Liu, Lantian Tian, Xiang Fang, Xianzhi Meng, Hongchi Jiang, Jiaren Liu, Lianxin Liu – 8 January 2013 – The increasing incidence of hepatocellular carcinoma (HCC) is of great concern not only in the United States but throughout the world. Although sorafenib, a multikinase inhibitor with antiangiogenic and antiproliferative effects, currently sets the new standard for advanced HCC, tumor response rates are usually quite low.

Lavrentios Papalavrentios, Emmanouil Sinakos, Danai Chourmouzi, Prodromos Hytiroglou, Konstantinos Drevelegas, Antonios Drevelegas, Evangelos Akriviadis – 8 January 2013

Karima Begriche, Julie Massart, Marie‐Anne Robin, Fabrice Bonnet, Bernard Fromenty – 8 January 2013 – The worldwide epidemic of obesity and insulin resistance favors nonalcoholic fatty liver disease (NAFLD). Insulin resistance (IR) in the adipose tissue increases lipolysis and the entry of nonesterified fatty acids (NEFAs) in the liver, whereas IR‐associated hyperinsulinemia promotes hepatic de novo lipogenesis. However, several hormonal and metabolic adaptations are set up in order to restrain hepatic fat accumulation, such as increased mitochondrial fatty acid oxidation (mtFAO).

Ruben Terg – 8 January 2013

Naga Chalasani – 7 January 2013

Alexa Schieck, Andreas Schulze, Caroline Gähler, Thomas Müller, Uwe Haberkorn, Alexander Alexandrov, Stephan Urban, Walter Mier – 4 January 2013 – The human hepatitis B virus (HBV) causes acute and chronic infections in humans and chimpanzees. HBV infects its hosts at minimal inoculation doses and replicates exclusively in hepatocytes. The viral determinants for the pronounced species specificity and the high efficacy to address hepatocytes in vivo are unknown.

Michael R. Lucey, Norah Terrault, Lolu Ojo, J. Eileen Hay, James Neuberger, Emily Blumberg, Lewis W. Teperman – 28 December 2012